In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Telerehabilitation in coronary artery disease (TRIC-Study), 12 months data

Session Poster Session III - Friday 08:30 - 12:30

Speaker Kurt Wallner

Congress : EuroPrevent 2015

  • Sub-topic : Telemedecine
  • Session type : Poster Session
  • FP Number : P481

Authors : K Wallner (Grossgmain,AT), J Altenberger (Grossgmain,AT), S Klausriegler (Grossgmain,AT), B Kogler (Grossgmain,AT), I Mairinger (Grossgmain,AT), R Mueller (Grossgmain,AT), R Rieder (Grossgmain,AT), H Zauner (Grossgmain,AT)

15 views

Authors:
K Wallner1 , J Altenberger1 , S Klausriegler1 , B Kogler1 , I Mairinger1 , R Mueller1 , R Rieder1 , H Zauner1 , 1SKA-RZ Grossgmain (PV) - Grossgmain - Austria ,

Citation:

Purpose
The aim was to evaluate feasibility, efficacy and safety of home-based telerehabilitation following shortened inpatient cardiac rehabilitation in comparison to a regular inpatient cardiac rehabilitation program in patients suffering uncomplicated coronary artery disease (CAD).

Methods
This prospective non-randomised parallel group study assigned 45 male patients for shortened 2 weeks inpatient rehabilitation followed by a 10 weeks telerehabilitation program (TRG) versus 47 patients who completed a conventional 4 weeks inpatient rehabilitation program (CG).  Outcome measures were assessed after 12 months using cardiopulmonary function (Watt (W)peak, Wpeak/kgBW(Bodywight), WVAT1(ventilatory aerobic treshold1), VO2peak/kg, VO2VAT1/kg, With L(lactate)2mmol/l, With L(lactate)4mmol/l), laboratory parameters (total cholesterol (TC), high density lipoprotein (HDL)-C; low density lipoprotein (LDL)-C; TC/HDL-C quotient)), physical parameter (body weight (BW); body mass index (BMI), waste circumference (WC), body fat (BF)).

Results
Baseline demographics were equally distributed between the groups, except age (CG younger).
No adverse events were observed in both groups during rehabilitation.
After 12 month in the TRG (n=41), Wpeak (+23,.1%; p<0.001), Wpeak/kgBW (+24.7%; p<0.001), WVAT1 (+11.2%; p=0.014), VO2peak/kg (+7.4%; p=0.008),  and VO2VAT1/kg (+4.7%; p=ns) were increased.
In the CG (n=45) only Wpeak and Wpeak/kgBW increased by +3.5% (p=ns) and +3.2% (p=ns) respectively. In contrast WVAT1, VO2VAT1/kg and VO2peak/kg decreased by -15.1% (p= 0.002), -11.1% (p= 0.006), and  -1.3%(p= ns) respectively.  The difference between TRG and CG was highly significant for VO2VAT1/kg (p=0.016), Wpeak (p=0.019), Wpeak/kg (p=0.005), and WVAT1 (p=0.002).  In TRG concentrations of  LDL-C (-22.7%; p< 0.001), TC (-14.5%; p< 0.001), TG (-17.2%; p=ns), and  TC/HDL-C (-16.9%; p= 0.001) decreased significantly during the twelve months. HDL-C (+1.2%; p=0.087) did not increase statistically significant.  In CG non of the laboratory parameters statistically significant changed.  After 12 months except HDL-C all parameters showed a statistically significant difference between the groups in favour of the TRG.  Physical parameters showed no statistical significant difference within and between the two groups after twelve months.  

Conclusions
Home-based telerehabilitation can be regarded as safe and feasible for patients with uncomplicated CAD. In addition we could show significant improvements due to physical fitness and change in risk factors in the TRG compared to regular four weeks inpatient rehabilitation.



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are